Share on StockTwits

Cempra Holdings (NASDAQ:CEMP) has been given an average recommendation of “Buy” by the nine brokerages that are currently covering the company, Analyst RN reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $15.63.

Shares of Cempra Holdings (NASDAQ:CEMP) traded down 2.45% on Tuesday, hitting $10.34. 66,258 shares of the company’s stock traded hands. Cempra Holdings has a 52-week low of $5.97 and a 52-week high of $15.39. The stock’s 50-day moving average is $11.70 and its 200-day moving average is $12.11. The company’s market cap is $343.2 million.

Cempra Holdings (NASDAQ:CEMP) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.42) by $0.09. The company had revenue of $2.07 million for the quarter, compared to the consensus estimate of $1.25 million. During the same quarter in the prior year, the company posted ($0.27) earnings per share. The company’s quarterly revenue was up 4046.0% on a year-over-year basis. On average, analysts predict that Cempra Holdings will post $-1.91 earnings per share for the current fiscal year.

Separately, analysts at Barclays initiated coverage on shares of Cempra Holdings in a research note on Tuesday. They set an “equal weight” rating and a $13.00 price target on the stock.

Cempra, Inc, formerly Cempra Holdings, LLC, is a development-stage and clinical-stage pharmaceutical company focused on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.